by Nisha Cooch, PhD | Sep 10, 2019 | Neurologists Resource Page One, Neurologists Resource Pages, Nursing Resource Page One, Nursing Resource Pages, Pediatricians Resource Page One, Pediatricians Resources, Radiology Resource Page One, Radiology Resources
Zolgensma, or onasemnogene abeparvovec, is an adeno-associated virus vector-based gene therapy that was approved by the FDA in May 2019. Given the newness of this therapy, it is important that healthcare providers are educated on specific information regarding the...
by Nisha Cooch, PhD | Jan 28, 2019 | Genetic Counselor Resource Page One, Genetic Counselor Resource Pages, Neurologists Resource Page One, Neurologists Resource Pages, Nursing Resource Page One, Nursing Resource Pages, Nutritionist Resource Page One, Nutritionist Resource Pages, Orthopedics Resource Page One, Orthopedics Resource Pages, Pediatricians Resource Page One, Pediatricians Resources, Physical Therapists Resource Page One, Physical Therapists Resource Pages, Pulmonologist Resource Page One, Pulmonologist Resource Pages, Radiology Resource Page One, Radiology Resources, Social Worker Resource Page One, Social Worker Resource Pages, Urologist Resource Page One, Urologist Resources
At the end of 2016, the U.S. Food and Drug Administration (FDA) approved nusinersen for the treatment of spinal muscular atrophy (SMA).1 Because of the high threshold for FDA approval, an abundance of data on nusinersen and its physiological effects on SMA patients...
by BNS Staff | Jan 15, 2019 | Neurologists Resource Page Two, Neurologists Resource Pages, Nursing Resource Page Two, Nursing Resource Pages, Radiology Resource Page One, Radiology Resources
Nusinersen is the first treatment available for children with spinal muscular atrophy (SMA). Before its approval in 2016, the U.S. Food and Drug Administration had not approved the use of any drug for SMA treatment.1 While the introduction of this new drug marks...
by BNS Staff | Oct 8, 2018 | Neurologists Resource Page One, Neurologists Resource Pages, Radiology Resource Page One, Radiology Resources
Nusinersen (Spinraza) is the first FDA-approved antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in adults and children.1,2 The oligonucleotide is administered intrathecally2; thus, administration is not as straightforward as an...
by BNS Staff | Aug 15, 2018 | Just Published, Nursing Resource Page One, Nursing Resource Pages, Pediatricians Resources, Pulmonologist Resource Page One, Pulmonologist Resource Pages, Radiology Resource Page One, Radiology Resources
Children with spinal muscular atrophy (SMA) often have difficulty with breathing and maintaining blood oxygenation in periods of relative wellness. As such, they often have limited reserve pulmonary and cardiovascular function. Thus during an acute illness, especially...